Polish company announces world’s first anti-COVID-19 medicine

Analysis

Photo by Savanevich Viktar/Shutterstock.com

Polish pharmaceutical company Biomed Lublin announced that it has finished production of the first batch of medicine made of plasma obtained from those who recovered from COVID-19 disease, Polandin.com reports. 

Photo by Savanevich Viktar/Shutterstock.com

The medicine, created via the process of the fractionation of plasma from patients who recovered or showed no symptoms of COVID-19 but were infected, contains specific anti-SARS-CoV-2 immunoglobulins. It will be released for non-commercial clinical trials in fourth quarter of 2020, according to the company.

“More than 3,000 samples of anti-SARS-CoV-2 immunoglobulin have been produced, which after the completion of the required quality tests, including product stability tests, will be submitted for clinical trials in four centres: in Lublin, Bytom, Białystok and Warsaw,” said Marcin Piróg, CEO of Biomed.

A total of 81,673 confirmed cases of the COVID-19 coronavirus infections were recorded in Poland as of the morning of September 23, which have resulted in 2,344 deaths and 65,561 recoveries, Polandin.com said.

ADVERTISEMENT

Bulgaria jobless rate falls to record low in August Figures

Bulgaria jobless rate falls to record low in August

Opposition parties to begin PM candidate primaries Elections

Opposition parties to begin PM candidate primaries

New editor-in-chief at Betone Studio Appointments

New editor-in-chief at Betone Studio

Budapest leaders make public transport free for under-14s City

Budapest leaders make public transport free for under-14s

SUPPORT THE BUDAPEST BUSINESS JOURNAL

Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.